RSNA VISIT US RSNA 2020
106th Scientific Assembly and Annual Meeting Online | Nov 29 – Dec 5 don't miss the poster presentation
Molecular Breast Imaging Screening in Dense Breasts:
Interim Analysis from the Density MATTERS Trial
Event ID: 20011150 | Public ID: BR-1A-57 VISIT RSNA KNOWING nothing was missed Improved Detection Reduced Biopsies Proven Savings increased invasive cancer detection rates reduction of benign biopsies in women with dense breast tissue compared to other modalities MBI added to screening mammography lowers cost per cancer detected MBI added to screening mammography lowers cost per cancer detected reduction of benign biopsies in women with dense breast tissue compared to other modalities Dense breast tissue and cancer both appear white on mammograms, making it difficult to distinguish between the two... similar to trying to find a snowflake in a snowstorm. MBI DETECTION earlier with lumaGEM Unknown Primary Screening Option Secondary Screening further evaluation of occult primary breast carcinoma for high risk patients for patients with dense breasts for equivocal conventional imaging findings Adjunct Screening BPI ACCURATE planning with Solo II Surgical Planning Monitor Treatment Recurrence Monitoring measure extent of disease for the best plan see the effectiveness of neoadjuvant therapy monitor previously diagnosed patients for breast cancer recurrence real-time PET guided biopsy capability Guided Biopsy SBI VISIT US 2020 European Congress of Radiology Virtual Exhibition Expo X1 #128 Online until Dec 31st See the future of molecular breast imaging. Registration is free of charge! VISIT EXPO

Your Total Molecular Breast Imaging Solution

Detection

Increase in invasive cancer detection rates

Reduction

Reduction of biopsies in women with dense breast tissue compared to other modalities

Fewer Limitations

Overcomes the limitations of other modalities

Savings

Provides lower costs per breast cancer detected in women with dense breast tissue

Case Studies 

MBI Prescribed Due to Dense Breast Tissue

Courtesy of Robin Shermis, MD ProMedica Toledo Hospital, Toledo, OH

BPI to Monitor Neoadjuvant Chemotherapy

Courtesy of Jane Nelson, MD, FACS. Austin Breast Center.

“

"I don’t think that there is any other method that would have found my cancer so that we could treat it and I can be here today. We did a Breast PET and my right breast lit up with the cancer. A breast biopsy confirmed triple negative breast cancer."

SallyBreast Cancer Survivor
“

"Molecular breast imaging offers women with dense breast tissue a much better chance at detecting breast cancer when treatment is easier and more successful. It has really changed the dynamics in our center. It is well tolerated by patients, quick to interpret and allows us to go over the results in real time with patients (acting on any findings on the same visit). The published data and our clinical experience has been exceptional. Our referring physicians and dense patients have a lot more peace of mind."

Dr. Robin Shermisradiologist and director of ProMedica Breast Care
“

"One of the important reasons I am a breast cancer survivor is because Gamma Medica’s LumaGEM detected breast cancer after my mammogram read negative – my accurate diagnosis empowered me to take action immediately. If you have dense breast tissue, MBI could save your life like it did for mine."

Diannepatient and breast cancer survivor
“

"I owe my life to the Breast PET scan."

ShawnAfter having an MRI and mammogram, Shawn still wasn’t getting definitive answers.